Recombinant Human Vitronectin,His (Human VTN,His)

92549ES60

100 μg

1,885

92549ES80

1 mg

13,185

Accession

P04004

Source

HEK293 Cells-derived human VTN protein, Met1-Leu478 with His tag at the C-terminus.

Molecular Weight

Approximately 53.7 kDa. As a result of glycosylation, it migrates as an approximately 68.1 kDa band in SDS-PAGE under reducing conditions.

AA Sequence

 MAPLRPLLIL ALLAWVALAD QESCKGRCTE GFNVDKKCQC DELCSYYQSC CTDYTAECKP QVTRGDVFTM PEDEYTVYDD GEEKNNATVH EQVGGPSLTS DLQAQSKGNP EQTPVLKPEE EAPAPEVGAS KPEGIDSRPE TLHPGRPQPP AEEELCSGKP FDAFTDLKNG SLFAFRGQYC YELDEKAVRP GYPKLIRDVW GIEGPIDAAF TRINCQGKTY LFKGSQYWRF EDGVLDPDYP RNISDGFDGI PDNVDAALAL PAHSYSGRER VYFFKGKQYW EYQFQHQPSQ EECEGSSLSA VFEHFAMMQR DSWEDIFELL FWGRTSAGTR QPQFISRDWH GVPGQVDAAM AGRIYISGMA PRPSLAKKQR FRHRNRKGYR SQRGHSRGRN QNSRRPSRAT WLSLFSSEES NLGANNYDDY RMDWLVPATC EPIQSVFFFS GDKYYRVNLR TRRVDTVDPP YPRSIAQYWL GCPAPGHL

Tag

His

Physical Appearance

Sterile Filtered White lyophilized (freeze-dried) powder.

Purity

> 90% by SDS-PAGE.

Biological Activity

Measured by the ability of the immobilized protein to support the adhesion of DU145 human prostate carcinoma cells. When cells are added to Vitronectin-coated plates (10 μg/mL and 100 μL/well), approximately >40% cells will adhere specifically after 30 minutes at 37℃.

Endotoxin

< 1.0 EU per 1μg of the protein by the LAL method.

Formulation

Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.

Reconstitution

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions.